RxDoctor Payments Data

David Strickland, MD

Ophthalmology · Louisville, KYNPI 1184999500

Payments from drug & device makers

What this record shows

Alcon accounts for 62.1% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $2,821, more than ten times the $74 reported in 2020.

$4,637in general payments, 2019–2025

Across 57 payments — averaging $81.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$3K
  • NEW World Medical,inc.$384
  • Johnson & Johnson Surgical Vision, Inc.$360
  • Glaukos Corporation$289
  • AbbVie$139
  • Tarsus Pharmaceuticals, Inc.$136
  • plus $452 from 7 others

What the payments were for

  • Travel & lodging$2,02044%
  • Food & beverage$2,61756%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,637 in reported general payments places this provider in the 80th percentile of 216 ophthalmology providers in Kentucky.

See all ophthalmology providers in Kentucky

Medicare billing

Part B allowed, 2024
$388,730
Medicare patients
1,393
Services billed
3,052

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast30$48,049
RestasisCyclosporine34$38,034
LumiganBimatoprost58$29,029
Cyclosporine23$22,706
RocklatanNetarsudil Mesylat/Latanoprost25$12,544
CombiganBrimonidine Tartrate/Timolol11$5,825
Fluorometholone45$3,089
Travoprost12$2,629
Prednisolone Acetate56$1,838
Latanoprost170$1,611
Tobramycin-DexamethasoneTobramycin/Dexamethasone27$1,104
ErythromycinErythromycin Base113$1,063
Doxycycline Monohydrate47$1,053
Ketorolac Tromethamine23$499
ValacyclovirValacyclovir Hcl14$407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$139$72,888103 claims
Aerie Pharmaceuticals, Inc.Rocklatan$114$12,54425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 216 ophthalmology providers in Kentucky.

Other ophthalmology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →